Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases.Raptor's lead product, PROCYSBI&trade (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30,…
Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor's lead product, PROCYSBI&trade (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI&trade marketing application in the European Union in the second half of 2013. Raptor's product pipeline may advance therapeutic options for additional indications. Raptor's management teamconsists of repeat entrepreneurs with the experience to build a successful company.
Team (1)
Join Axial's Private M&A Platform
Raptor Pharmaceuticals Corp. (NasdaqCM:RPTP) connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
